2.11
-0.09(-4.09%)
Currency In USD
| Previous Close | 2.2 |
| Open | 2.24 |
| Day High | 2.3 |
| Day Low | 2.11 |
| 52-Week High | 2.48 |
| 52-Week Low | 0.83 |
| Volume | 5.39M |
| Average Volume | 4.36M |
| Market Cap | 222.4M |
| PE | -7.54 |
| EPS | -0.28 |
| Moving Average 50 Days | 1.78 |
| Moving Average 200 Days | 1.65 |
| Change | -0.09 |
If you invested $1000 in SELLAS Life Sciences Group, Inc. (SLS) 10 years ago, it would be worth $0.05 as of December 18, 2025 at a share price of $2.11. Whereas If you bought $1000 worth of SELLAS Life Sciences Group, Inc. (SLS) shares 5 years ago, it would be worth $302.73 as of December 18, 2025 at a share price of $2.11.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025
GlobeNewswire Inc.
Dec 07, 2025 11:00 PM GMT
SLS009 in combination with AZA/VEN achieved a 46% overall response rate across all cohorts, a 58% overall response rate in patients with one prior line of therapy, and encouraging survival outcomes in heavily-pretreated AML-MR following prior VEN-bas
SELLAS Life Sciences Announces Presentation of Phase 2 Data of SLS009 in Combination with Azacitidine and Venetoclax in Relapsed/Refractory AML with MDS-Related Changes (AML-MR) at the 2025 American Society of Hematology (ASH) Annual Meeting
GlobeNewswire Inc.
Nov 03, 2025 2:00 PM GMT
NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indic
SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds
GlobeNewswire Inc.
Oct 27, 2025 12:30 PM GMT
NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indica